Hepatocellular Carcinoma Treatment and Prognosis
This cluster of papers focuses on the management, diagnosis, and treatment of hepatocellular carcinoma (HCC), also known as liver cancer. It covers various aspects including clinical practice guidelines, radiofrequency ablation, use of sorafenib, liver resection, and survival rates.
Papers listed on taxonomy pages are the top few works per node from the OpenAlex snapshot. That list is not exhaustive and is not an endorsement. The topic map and the journal registry remain separate: there is still no authoritative topic-to-venue or topic-to-organization edge. Search is a lexical lookup, not a claim that a venue publishes a topic.
Most cited
- Sorafenib in Advanced Hepatocellular Carcinoma
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- Management of Hepatocellular Carcinoma: An Update Δσ
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
- Hepatocellular carcinoma
Most recent
- Revisiting HAIC and systemic treatment for initially diagnosed HCC with major portal vein (Vp3/4) tumor thrombosis
- Stereotactic body radiation therapy for hepatocellular carcinoma: 2026 expert consensus-based practical recommendation of the Korean Liver Cancer Association
- High immunosuppressants variability adversely affects post-transplant recurrence for patients with hepatocellular carcinoma
- Blood-based CRC screening: closer, but not there yet
- The value of biopsy in the diagnosis and management of hepatocellular carcinoma: guideline interpretation and recent advances
- Mac‐2 Binding Protein Glycosylation Isomer ( M2BPGi )–Based Risk Stratification Refined by Tumor Metabolic Activity in Hepatocellular Carcinoma